Zeria Pharmaceutical Co., Ltd.
4559・Prime Market・Pharmaceuticals
Business
Zeria Pharmaceutical Co., Ltd., founded in 1955, is a pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange. The company is centered on two core businesses: the Prescription Pharmaceuticals Business (net sales of ¥61,626 million) and the Consumer Healthcare Business (net sales of ¥27,382 million), with total group net sales of ¥89,159 million in FY2026 (ending March 2026). The Prescription Pharmaceuticals Business specializes in the gastrointestinal field, developing products such as the ulcerative colitis treatment Asacol and the Clostridioides difficile infection treatment Dificlir (domestic brand name: Dafclir) for global markets including Europe and Asia. The Consumer Healthcare Business sells OTC pharmaceuticals, health foods, and cosmetics both domestically and internationally, led by the mainstay Hepalyse Group. The overseas sales ratio has reached 59.3%, reflecting the company's growing presence as a global enterprise.
Business Model
In the Prescription Pharmaceuticals Business, R&D resources are concentrated on the gastrointestinal field, combining the development of proprietary original products (such as acotiamide) with in-licensing from external partners (Dificlir (domestic brand name: Dafclir), Vitasa, ferric carboxymaltose, etc.), and maximizing revenue through the company's own European sales network operated via its Swiss subsidiary Tillotts Pharma AG. In the Consumer Healthcare Business, advertising investment is concentrated on branded products such as the Hepalyse Group to continuously stimulate demand in the OTC market. The company practices a circular management approach in which stable earnings from both businesses fund the next round of M&A and R&D investment.
Company Strengths
Through the Swiss subsidiary Tillotts Pharma AG and its eight subsidiaries, the company has built a proprietary sales network in major European countries. Dificlir has achieved continued revenue growth in countries with large market sizes such as France and Germany, while Asacol has also performed well in overseas markets following the normalization of supply. Leveraging its status as a first-line recommended drug under European guidelines, the company is maximizing the strengths of its proprietary network.
The "Hepalyse Group," cultivated since its launch in 1996, has continued to successfully stimulate demand through aggressive investment in advertising and sales promotion. In FY2025 (fiscal year 2025), the company newly launched "Hepalyse Ichonaifukueki EX" and "Hepalyse Icho Drink," expanding its product lineup. It functions as a core brand supporting the Consumer Healthcare Business's net sales of ¥27,382 million and operating profit of ¥6,360 million.
The Prescription Pharmaceuticals Business (operating profit of ¥12,176 million) and the Consumer Healthcare Business (operating profit of ¥6,360 million) generate earnings in a mutually complementary manner. This structure, in which one business supports the other even when the operating environment for the other deteriorates, has enabled continuous growth in both net sales and operating profit from FY2022 (ending March 2022) through FY2026 (ending March 2026). This stable foundation serves as the source of funds for M&A and R&D investment.
ENVALITH's Perspective
Performance Trend
Revenue grew for five consecutive fiscal years, rising from ¥59,533 million in FY2022 (ended March 2022) to ¥89,159 million in FY2026 (ending March 2026), but the growth rate decelerated from 15.3% in the previous fiscal year to 2.1% in the current fiscal year. Operating income increased only slightly to ¥12,374 million (up 1.4% year on year), and the operating margin remained nearly flat at 13.9% (versus 14.0% in the previous fiscal year). As an external factor, a swing from a foreign exchange gain of ¥634 million in the previous fiscal year to a foreign exchange loss of ¥1,356 million in the current fiscal year pushed down ordinary income by 14.0%. Comprehensive income increased substantially to ¥20,927 million (up 75.1% year on year), with increases in the foreign currency translation adjustment of ¥7,621 million and the remeasurements of defined benefit plans of ¥3,927 million boosting net assets. The equity ratio improved to 60.3% (from 56.3% in the previous fiscal year).
Growth Strategy
Aiming for consolidated net sales of ¥95.0 billion through accelerated global expansion in Europe and Asia and cultivation of new domestic products
Dificlir continues to maintain a growth trend in major European countries such as France and Germany. Following the recovery of production facilities at the contract manufacturer, supply of Asacol has normalized, and full-year FY2026 (ending March 2026) results turned to an increase in sales. For FY2027 (ending March 2026)—assuming continued strong overseas performance of both products—an increase in sales for the Prescription Pharmaceuticals Business is forecast.
In December 2025, the restriction on the medication administration period was lifted, and efforts are underway to rapidly build the market, particularly in the nephrology, dialysis, and cardiovascular fields. Planning for evidence-generation activities has begun, and post-marketing drug development activities are being ramped up in earnest. Vitasa is expected to serve as a driver of sales growth for the domestic Prescription Pharmaceuticals Business in FY2027 (ending March 2026).
Phase III trials with Agastra-Lab s.r.l. are underway in Europe, the United States, and Canada. Regulatory approval applications are pending in Vietnam, while approvals have already been obtained in Nicaragua and Costa Rica. Applications are also pending in Colombia and Panama. Domestically, subject recruitment for the pediatric Phase III trial has been completed, and work is underway to compile the trial results.
In addition to growth in sales of the Hepalyse Group, an increase in sales is expected for FY2027 (ending March 2026), driven by a recovery in sales of core products such as the Chondroitin Group and the With One Group, as well as contributions from product groups following the core products. Overseas expansion also continues, including Hepalyse WT and Chondro Support Active for the Taiwanese market.
During FY2026 (ending March 2026), Kenso Seiyaku Co., Ltd. was dissolved through an absorption-type merger with Zeria Pharmaceutical Co., Ltd. as the surviving company, and it was removed from the scope of consolidation. This move aims to improve efficiency by consolidating manufacturing and management functions and to advance the optimization of group management.
Last updated: July 19, 2026